Medical Grand Rounds

Mark V. Williams, MD
Director, Hospital Medicine Unit, Emory University School of Medicine, Atlanta, Georgia

Address: Mark V. Williams, MD, Department of Medicine, Emory University School of Medicine, 69 Butler Street SE, Atlanta, GA 30303

Mark V. Williams, MD
Director, Hospital Medicine Unit, Emory University School of Medicine, Atlanta, Georgia

Address: Mark V. Williams, MD, Department of Medicine, Emory University School of Medicine, 69 Butler Street SE, Atlanta, GA 30303

Mark V. Williams, MD
Director, Hospital Medicine Unit, Emory University School of Medicine, Atlanta, Georgia

Address: Mark V. Williams, MD, Department of Medicine, Emory University School of Medicine, 69 Butler Street SE, Atlanta, GA 30303

Natalie G. Correia, DO
Department of General Internal Medicine, Section of Hospital Medicine, Cleveland Clinic

Address: Natalie G. Correia, DO, Department of General Internal Medicine, E13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Natalie G. Correia, DO
Department of General Internal Medicine, Section of Hospital Medicine, Cleveland Clinic

Address: Natalie G. Correia, DO, Department of General Internal Medicine, E13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Natalie G. Correia, DO
Department of General Internal Medicine, Section of Hospital Medicine, Cleveland Clinic

Address: Natalie G. Correia, DO, Department of General Internal Medicine, E13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.

Glen D. Solomon, MD
Senior Medical Director, Department of Medical and Scientific Affairs, US Human Health, Merck and Company, Inc; consultant, Departments of Neurology and General Internal Medicine, The Cleveland Clinic

Address: Glen D. Solomon, MD, 42 Bradford Lane, Oak Brook, IL 60523

Dr. Solomon discusses therapies that are either investigative or not yet labeled for the use under discussion.

Glen D. Solomon, MD
Senior Medical Director, Department of Medical and Scientific Affairs, US Human Health, Merck and Company, Inc; consultant, Departments of Neurology and General Internal Medicine, The Cleveland Clinic

Address: Glen D. Solomon, MD, 42 Bradford Lane, Oak Brook, IL 60523

Dr. Solomon discusses therapies that are either investigative or not yet labeled for the use under discussion.

Glen D. Solomon, MD
Senior Medical Director, Department of Medical and Scientific Affairs, US Human Health, Merck and Company, Inc; consultant, Departments of Neurology and General Internal Medicine, The Cleveland Clinic

Address: Glen D. Solomon, MD, 42 Bradford Lane, Oak Brook, IL 60523

Dr. Solomon discusses therapies that are either investigative or not yet labeled for the use under discussion.

Daniel J. Clauw, MD
Associate Professor of Medicine and Orthopaedics, Georgetown University Medical Center,Washington, DC

Address: Daniel J. Clauw, MD, Georgetown University Medical Center, 3800 Reservoir Rd, Washington, DC 20007

Dr. Clauw serves as a consultant for and has received grant or research support from Cypress Biosciences.

This article discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.

Daniel J. Clauw, MD
Associate Professor of Medicine and Orthopaedics, Georgetown University Medical Center,Washington, DC

Address: Daniel J. Clauw, MD, Georgetown University Medical Center, 3800 Reservoir Rd, Washington, DC 20007

Dr. Clauw serves as a consultant for and has received grant or research support from Cypress Biosciences.

This article discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.

Daniel J. Clauw, MD
Associate Professor of Medicine and Orthopaedics, Georgetown University Medical Center,Washington, DC

Address: Daniel J. Clauw, MD, Georgetown University Medical Center, 3800 Reservoir Rd, Washington, DC 20007

Dr. Clauw serves as a consultant for and has received grant or research support from Cypress Biosciences.

This article discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.